Regulus Therapeutics initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months. Regulus’ team expects to share further updates as they become available, including topline data from the third cohort in the middle of this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus files to sell 62.5M shares of common stock for holders
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
- Regulus reports Q4 EPS (40c), consensus (39c)
- Regulus options imply 25.8% move in share price post-earnings
- Regulus price target lowered to $11 from $12 at Canaccord
